a modified vaccinia ankara virus (mva) vaccine expressing african horse sickness virus (ahsv) vp2 protects against ahsv challenge in an ifnar ？？ mouse model修改牛痘安卡拉病毒(mva)疫苗表达非洲马瘟病毒(ahsv)vp2防止ahsv挑战一个ifnar 小鼠模型.pdfVIP

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR 2/ 2 Mouse Model 1 2 2 1 Javier Castillo-Olivares *, Eva Calvo-Pinilla , Isabel Casanova , Katarzyna Bachanek-Bankowska , 3 1 2 2 1 Rachael Chiam , Sushila Maan , Jose Maria Nieto , Javier Ortego , Peter Paul Clement Mertens 1 Institute for Animal Health, Pirbright, Woking, Surrey, United Kingdom, 2 Centro en Investigacion y Sanidad Animal (CISA), Valdeolmos, Madrid, Spain, 3 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom Abstract African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recom